ZENTIVA S.A. (SCD) - Total Liabilities
Based on the latest financial reports, ZENTIVA S.A. (SCD) has total liabilities worth RON350.60 Million RON (≈ $80.50 Million USD) as of March 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
ZENTIVA S.A. - Total Liabilities Trend (2019–2024)
This chart illustrates how ZENTIVA S.A.'s total liabilities have evolved over time, based on quarterly financial data. See SCD current assets to equity ratio to evaluate short-term liquidity relative to the company's equity base.
ZENTIVA S.A. Competitors by Total Liabilities
The table below lists competitors of ZENTIVA S.A. ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Patria Investments Ltd
NASDAQ:PAX
|
USA | $1.11 Billion |
|
Shandong Keyuan Pharmaceutical Co. Ltd. A
SHE:301281
|
China | CN¥222.24 Million |
|
Swissquote Group Holding SA
SW:SQN
|
Switzerland | CHF14.65 Billion |
|
EZTEC Empreendimentos e Participações S.A
SA:EZTC3
|
Brazil | R$1.79 Billion |
|
Dodla Dairy Limited
NSE:DODLA
|
India | Rs4.01 Billion |
|
Shengyuan Environmental Protection
SHE:300867
|
China | CN¥4.91 Billion |
|
Jiangsu Jibeier Pharmaceutical Co Ltd
SHG:688566
|
China | CN¥222.75 Million |
|
Plato Income Maximiser Ltd
AU:PL8
|
Australia | AU$10.14 Million |
Liability Composition Analysis (2019–2024)
This chart breaks down ZENTIVA S.A.'s total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see SCD market cap overview.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 4.85 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.23 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.19 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how ZENTIVA S.A.'s debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for ZENTIVA S.A. (2019–2024)
The table below shows the annual total liabilities of ZENTIVA S.A. from 2019 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-09-30 | RON292.14 Million ≈ $67.08 Million |
-5.22% |
| 2023-09-30 | RON308.24 Million ≈ $70.78 Million |
+49.76% |
| 2022-09-30 | RON205.82 Million ≈ $47.26 Million |
+29.58% |
| 2021-09-30 | RON158.83 Million ≈ $36.47 Million |
-35.93% |
| 2020-09-30 | RON247.90 Million ≈ $56.92 Million |
-21.53% |
| 2019-09-30 | RON315.91 Million ≈ $72.54 Million |
-- |
About ZENTIVA S.A.
Zentiva S.A. engages in the production and marketing of preparations and medicines for human use in Romania and internationally. The company develops pharmaceutical products in various therapeutic areas, such as cardiovascular diseases, anti-inflammatory and pain-relieving medications, urologists, blood diseases, gastrointestinal and metabolic disorders, central nervous system, infections, respir… Read more